Ítem
Solo Metadatos

The impact of acute lymphoblastic leukemia treatment on central nervous system results in Bogota, Colombia

Mostrar el registro sencillo de la publicación
dc.creatorH, Maria Teresa Amparo Buendiaspa
dc.creatorLozano, Juan Manuelspa
dc.creatorSuarez, Gloria Elenaspa
dc.creatorA, Carlos Saavedraspa
dc.creatorGuevara, Gonzalospa
dc.date.accessioned2020-05-25T23:56:25Z
dc.date.available2020-05-25T23:56:25Z
dc.date.created2008spa
dc.description.abstractTo improve the outcome of children with acute lymphoblastic leukemia (ALL) treated at the National Cancer Institute, Bogota, Colombia, a protocol based on the BFM-90 (Berlin, Frankfurt, Munster study) and the LSA2L 2 regimens was implemented in the year 1993. The patients were classified as being standard risk (SR) or high risk (HR) according to clinical criteria, to which cytogenetic information and day-8 prednisone response were also added. A 123-patient cohort entered the study, 18 of them being considered SR and 105 HR. There was a 94% 10 years' event-free-survival rate for the SR group and 36% for the HR group. Decreased induction death rate (7% vs. 14%), increased complete remission (CR) rate (81% vs. 75%), and continuous CR (45% vs. 33%) were found in comparison with the previous study. A significant improvement was achieved in relapse rate, 44% to 28% (P=0.029), mainly due to reduced central nervous system relapse rate from 16% to 6% (P=0.037), whereas the number of patients receiving cranial radiation was reduced to 55%. A major problem concerned the increased CR mortality rate, 5% to 14% (P=0.06). Improved supportive care therapy and socioeconomic conditions will hopefully reduce the CR mortality rate in the future. © 2008 by Lippincott Williams and amp; Wilkins.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1097/MPH.0b013e31817e4a7d
dc.identifier.issn10774114
dc.identifier.issn15363678
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/22419
dc.language.isoengspa
dc.publisherLippincott Williams and Wilkinsspa
dc.relation.citationEndPage650
dc.relation.citationIssueNo. 9
dc.relation.citationStartPage643
dc.relation.citationTitleJournal of Pediatric Hematology/Oncology
dc.relation.citationVolumeVol. 30
dc.relation.ispartofJournal of Pediatric Hematology/Oncology, ISSN:10774114, 15363678, Vol.30, No.9 (2008); pp. 643-650spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-66249140940&doi=10.1097%2fMPH.0b013e31817e4a7d&partnerID=40&md5=e598420d36c5852e7b9e3e3437f5b342spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordAntineoplastic agentspa
dc.subject.keywordpreschooleng
dc.subject.keywordCyclophosphamidespa
dc.subject.keywordCytarabinespa
dc.subject.keywordDaunorubicinspa
dc.subject.keywordDexamethasonespa
dc.subject.keywordDoxorubicinspa
dc.subject.keywordFolinate calciumspa
dc.subject.keywordMercaptopurinespa
dc.subject.keywordMethotrexatespa
dc.subject.keywordPrednisonespa
dc.subject.keywordAcute lymphoblastic leukemiaspa
dc.subject.keywordAdolescentspa
dc.subject.keywordArticlespa
dc.subject.keywordCancer chemotherapyspa
dc.subject.keywordCancer mortalityspa
dc.subject.keywordCancer radiotherapyspa
dc.subject.keywordCancer regressionspa
dc.subject.keywordCancer relapsespa
dc.subject.keywordCancer riskspa
dc.subject.keywordCancer survivalspa
dc.subject.keywordCentral nervous systemspa
dc.subject.keywordChildspa
dc.subject.keywordColombiaspa
dc.subject.keywordControlled studyspa
dc.subject.keywordCytogeneticsspa
dc.subject.keywordDrug dose reductionspa
dc.subject.keywordDrug megadosespa
dc.subject.keywordFemalespa
dc.subject.keywordHumanspa
dc.subject.keywordInfantspa
dc.subject.keywordMajor clinical studyspa
dc.subject.keywordMalespa
dc.subject.keywordMultiple cycle treatmentspa
dc.subject.keywordPreschool childspa
dc.subject.keywordPriority journalspa
dc.subject.keywordSchool childspa
dc.subject.keywordTreatment outcomespa
dc.subject.keywordTreatment responsespa
dc.subject.keywordAdolescentspa
dc.subject.keywordAntineoplastic combined chemotherapy protocolsspa
dc.subject.keywordCentral nervous system neoplasmsspa
dc.subject.keywordChildspa
dc.subject.keywordChildeng
dc.subject.keywordCohort studiesspa
dc.subject.keywordColombiaspa
dc.subject.keywordCranial irradiationspa
dc.subject.keywordCytogenetic analysisspa
dc.subject.keywordHumansspa
dc.subject.keywordInfantspa
dc.subject.keywordPrecursor cell lymphoblastic leukemia-lymphomaspa
dc.subject.keywordPrednisonespa
dc.subject.keywordRecurrencespa
dc.subject.keywordRemission inductionspa
dc.subject.keywordRiskspa
dc.subject.keywordSurvival ratespa
dc.subject.keywordCns-leukemiaspa
dc.subject.keywordDeveloping countryspa
dc.subject.keywordIntensive chemotherapyspa
dc.subject.keywordPediatric allspa
dc.titleThe impact of acute lymphoblastic leukemia treatment on central nervous system results in Bogota, Colombiaspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos